Biointerface membranes incorporating bioactive agents
First Claim
1. A biointerface membrane comprising a nonresorbable solid portion and a bioactive agent, wherein the nonresorbable solid portion comprises a plurality of interconnected cavities adapted to support a tissue ingrowth in vivo, and wherein the bioactive agent is incorporated into the biointerface membrane and is adapted to modify a tissue response.
1 Assignment
0 Petitions
Accused Products
Abstract
A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.
1324 Citations
55 Claims
- 1. A biointerface membrane comprising a nonresorbable solid portion and a bioactive agent, wherein the nonresorbable solid portion comprises a plurality of interconnected cavities adapted to support a tissue ingrowth in vivo, and wherein the bioactive agent is incorporated into the biointerface membrane and is adapted to modify a tissue response.
-
41. A biointerface membrane for implantation in a soft tissue, the membrane comprising:
-
a first domain, wherein the first domain comprises a plurality of interconnected cavities and a solid portion, and wherein a substantial number of the cavities are greater than or equal to about 0.6 μ
m in at least one dimension;
a second domain that allows a passage of an analyte and that is impermeable to cells or cell processes; and
a bioactive agent incorporated into the first domain or the second domain, and which is adapted to modify an in vivo tissue response. - View Dependent Claims (42, 43, 44, 46, 47, 48)
-
-
45. The biointerface membrane according to claim 45, wherein the cavities are from about 90 μ
- m to about 370 μ
m in at least one dimension.
- m to about 370 μ
-
49. An implantable device, the device comprising a sensing region for sensing an analyte and a biointerface membrane adjacent to the sensing region, wherein the membrane is configured to modify an in vivo tissue response by a porous architecture and by incorporation of a bioactive agent in the membrane.
-
50. A biointerface membrane suitable for implantation in a soft tissue, the membrane comprising a plurality of interconnected cavities and a solid portion, wherein the plurality of interconnected cavities and the solid portion are configured to redirect a fibrous tissue contracture, thereby interfering with barrier cell layer formation within or around the first domain, and wherein the biointerface membrane further comprises a bioactive agent adapted to modify a tissue response.
-
51. An implantable glucose device, the device comprising a nonresorbable biointerface membrane adapted to modify an in vivo tissue response, the membrane comprising a porous membrane architecture and having a bioactive agent incorporated therein.
-
52. A biointerface membrane for use with an implantable device, the biointerface membrane comprising:
-
a first domain distal to the implantable device, wherein the first domain comprises an open-cell configuration;
a second domain proximal to the implantable device, wherein the second domain is impermeable to cells or cell processes; and
a bioactive agent incorporated within the membrane. - View Dependent Claims (53)
-
-
54. A method of monitoring an analyte concentration, the method comprising the steps of:
-
providing a host;
providing an implantable device, the implantable device comprising a housing comprising electronic circuitry, and at least one sensing region operably connected to the electronic circuitry of the housing, the sensing region comprising a biointerface membrane, the biointerface membrane comprising a first domain distal to the implantable device, wherein the first domain comprises an open-cell configuration, the biointerface membrane comprising a second domain proximal to the implantable device, wherein the second domain is impermeable to cells or cell processes, and wherein the biointerface membrane comprises a bioactive agent incorporated into the biointerface membrane;
implanting the device in the host whereby the bioactive agent is delivered to the tissue of the host; and
measuring an analyte concentration. - View Dependent Claims (55)
-
Specification